Sanofi Consumer Healthcare reports 33% revenue growth in Q1 FY26; PAT rises 36%
Domestic sales increased 15.5%, supported by the relaunch of previously recalled products in the market
Domestic sales increased 15.5%, supported by the relaunch of previously recalled products in the market
The company achieved 20% EBITDA profitability in Bengaluru and reached operational profitability across all its active cities
The company allocated €56 million to research and development for next-generation line solutions
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
For the fourth quarter, revenue surged 47% year-on-year to Rs. 2,510 million, driven by a 23% rise in domestic sales and a 9.3x jump in export sales
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
The base Gland business posted ?11,790 million in revenue, up 16% YoY
Subscribe To Our Newsletter & Stay Updated